A major announcement
Invivyd—developer of Pemgarda (FDA-authorized) and the next-generation antibody VYD2311—has launched the SPEAR Study Group (Spike Protein Elimination And Recovery). Led by Drs. Michael Peluso, Amy Proal, and David Putrino, SPEAR will design controlled, multi-centre trials that:
• Use Pemgarda or VYD2311 (not earlier antibodies like AER002).
• Focus on people with Long COVID or Post-Vaccination Syndrome who show evidence of persistent spike protein / viral reservoirs.
• Measure safety, immune changes, and exploratory symptom improvement—laying the groundwork for definitive efficacy studies.
A prior mAb trial (AER002) did not improve symptoms, but experts believe higher-potency antibodies—and proper dosing—are key. Pemgarda and VYD2311 bring that fresh potential.
Where Canada stands
Pemgarda is still unavailable here; Health Canada lacks an immune-bridging pathway.
No Canadian trial sites have (yet) been announced for SPEAR.
Without policy change, patients may be shut out of the very studies that could help them.
Petition progress & renewed hope
We’ve reached 722 signatures! Each name is a reminder that real people are still suffering, waiting, and hoping.
SPEAR shows science is moving; with the right policy, Canadians can benefit too.
Next steps
Contact Invivyd & SPEAR investigators to request Canadian sites.
We’ve sent our third follow-up to Health Canada, plus a phone call—highlighting SPEAR, Pemgarda’s Phase 3 data, and the urgent need for an immune-bridging pathway. We’re awaiting a response.
Keep pushing: contact your MP, provincial health minister, and Health Canada. Explain why Canada must join this wave of research.
🔗 Petition: https://www.change.org/MAbsForCanadaNOW
Thank you for standing with immunocompromised Canadians and everyone living with Long COVID. This new initiative gives real hope that effective treatments could finally be within reach—and together, we can help bring them home.
In solidarity,
Rowan
#MAbsForCanadaNOW
#LongCOVIDTrialsNOW
#ProtectImmunocompromised #COVID19IsNotOver